Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lili Mao

Showing results (101-110 of 146) with videos related to

Pageof 15
Sort By:
Cancer Management and Research|May 7, 2025
Real-World Efficacy and Safety of Anti-PD-1 Antibody Plus Apatinib and Temozolomide for Advanced Acral MelanomaJiaran Zhang, Huichun Tian, Lili Mao, et al.
Journal of Cancer|April 1, 2020
A Functional Synonymous Variant in <i>PDGFRA</i> Is Associated with Better Survival in Acral MelanomaJie Dai, Lu Yang, Tianxiao Xu, et al.
European Journal of Cancer (Oxford, England : 1990)|September 22, 2022
Cumulative incidence and risk factors of brain metastasis for acral and mucosal melanoma patients with stages I-IIIYang Wang, Bin Lian, Lu Si, et al.
Ebiomedicine|April 27, 2020
Phase 1 trial of vorolanib (CM082) in combination with everolimus in patients with advanced clear-cell renal cell carcinomaXinan Sheng, Xieqiao Yan, Zhihong Chi, et al.
Clinical and Translational Medicine|January 6, 2025
Atezolizumab plus bevacizumab in patients with unresectable or metastatic mucosal melanoma: 3-year survival update and multi-omics analysisJie Dai, Tianxiao Xu, Lifeng Li, et al.
Innovation (Cambridge (Mass.))|June 17, 2024
IBI310 (anti-CTLA-4 antibody) monotherapy or in combination with sintilimab in advanced melanoma or urothelial carcinomaChuanliang Cui, Juan Li, Yue Yang, et al.
Cancer Research Communications|May 2, 2024
Comparative Epigenetic Profiling Reveals Distinct Features of Mucosal Melanomas Associated with Immune Cell Infiltration and Their Clinical ImplicationsJie Dai, Jia Jia, Fanshuang Zhang, et al.
BMC Cancer|May 20, 2022
Safety, activity, and pharmacokinetics of camrelizumab in advanced Asian melanoma patients: a phase I studyLi Zhou, Xiaowen Wu, Zhihong Chi, et al.
European Journal of Cancer (Oxford, England : 1990)|February 8, 2023
Apatinib combined with camrelizumab in advanced acral melanoma patients: An open-label, single-arm phase 2 trialXuan Wang, Xiaowen Wu, Yue Yang, et al.
Experimental Hematology & Oncology|June 2, 2026
Long-term survival benefit of neoadjuvant oncolytic virus plus PD-1 blockade in acral melanoma: implications of STING in resistance and potential therapyQian Zhao, Yu Du, Lifeng Li, et al.
Pageof 15

Showing results (101-110 of 146) with videos related to

Sort By:
Pageof 15
Cancer Management and Research|May 7, 2025
Real-World Efficacy and Safety of Anti-PD-1 Antibody Plus Apatinib and Temozolomide for Advanced Acral MelanomaJiaran Zhang, Huichun Tian, Lili Mao, et al.
Journal of Cancer|April 1, 2020
A Functional Synonymous Variant in <i>PDGFRA</i> Is Associated with Better Survival in Acral MelanomaJie Dai, Lu Yang, Tianxiao Xu, et al.
European Journal of Cancer (Oxford, England : 1990)|September 22, 2022
Cumulative incidence and risk factors of brain metastasis for acral and mucosal melanoma patients with stages I-IIIYang Wang, Bin Lian, Lu Si, et al.
Ebiomedicine|April 27, 2020
Phase 1 trial of vorolanib (CM082) in combination with everolimus in patients with advanced clear-cell renal cell carcinomaXinan Sheng, Xieqiao Yan, Zhihong Chi, et al.
Clinical and Translational Medicine|January 6, 2025
Atezolizumab plus bevacizumab in patients with unresectable or metastatic mucosal melanoma: 3-year survival update and multi-omics analysisJie Dai, Tianxiao Xu, Lifeng Li, et al.
Innovation (Cambridge (Mass.))|June 17, 2024
IBI310 (anti-CTLA-4 antibody) monotherapy or in combination with sintilimab in advanced melanoma or urothelial carcinomaChuanliang Cui, Juan Li, Yue Yang, et al.
Cancer Research Communications|May 2, 2024
Comparative Epigenetic Profiling Reveals Distinct Features of Mucosal Melanomas Associated with Immune Cell Infiltration and Their Clinical ImplicationsJie Dai, Jia Jia, Fanshuang Zhang, et al.
BMC Cancer|May 20, 2022
Safety, activity, and pharmacokinetics of camrelizumab in advanced Asian melanoma patients: a phase I studyLi Zhou, Xiaowen Wu, Zhihong Chi, et al.
European Journal of Cancer (Oxford, England : 1990)|February 8, 2023
Apatinib combined with camrelizumab in advanced acral melanoma patients: An open-label, single-arm phase 2 trialXuan Wang, Xiaowen Wu, Yue Yang, et al.
Experimental Hematology & Oncology|June 2, 2026
Long-term survival benefit of neoadjuvant oncolytic virus plus PD-1 blockade in acral melanoma: implications of STING in resistance and potential therapyQian Zhao, Yu Du, Lifeng Li, et al.
Pageof 15